title: Effectiveness of trivalent seasonal and monovalent influenza A(H1N1)2009 vaccines in population with major chronic conditions of Navarre, Spain: 2010/11 mid-season analysis.
abstract: We defined a cohort of people with major chronic conditions (152,585 subjects) in Navarre, Spain, using electronic records from physicians, to obtain 2010/11 mid-season estimates of influenza vaccine effectiveness. The adjusted estimates of the effectiveness of the 2010/11 trivalent influenza vaccine were 31% (95% confidence interval (CI): 20–40%) in preventing medically attended influenza-like illness, and 58% (95% CI: 11–80%) in preventing laboratory-confirmed influenza. Having received the monovalent influenza A(H1N1)2009 vaccine in the 2009/10 season had an independent preventive effect against medically attended influenza-like illness (17%, 95% CI: 1–30%), and having received both vaccines had 68% (95% CI: 23–87%) effectiveness in preventing laboratory-confirmed influenza.
authors.affiliation: Public Health Institute of Navarre, Pamplona, Spain. jcastilc@navarra.es
authors.forename: J
authors.initials: J
authors.lastname: Castilla
authors.forename: J
authors.initials: J
authors.lastname: Moran
authors.forename: V
authors.initials: V
authors.lastname: Martinez-Artola
authors.forename: G
authors.initials: G
authors.lastname: Reina
authors.forename: I
authors.initials: I
authors.lastname: Martinez-Baz
authors.forename: M
authors.initials: M
authors.lastname: Garcia Cenoz
authors.forename: N
authors.initials: N
authors.lastname: Alvarez
authors.forename: F
authors.initials: F
authors.lastname: Irisarri
authors.forename: M
authors.initials: M
authors.lastname: Arriazu
authors.forename: F
authors.initials: F
authors.lastname: Elia
authors.forename: E
authors.initials: E
authors.lastname: Salcedo
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002648:Child; D002675:Child, Preschool; D002908:Chronic Disease; D016001:Confidence Intervals; D004196:Disease Outbreaks / Q000517:prevention & control*; D005260:Female; D006801:Humans; D015994:Incidence; D007223:Infant; D053118:Influenza A Virus, H1N1 Subtype / Q000276:immunology*; D007252:Influenza Vaccines / Q000276:immunology* / Q000627:therapeutic use; D007251:Influenza, Human / Q000453:epidemiology / Q000276:immunology / Q000517:prevention & control* / Q000821:virology; D008297:Male; D008875:Middle Aged; D011159:Population Surveillance; D011320:Primary Health Care; D011446:Prospective Studies; D012621:Seasons; D013030:Spain / Q000453:epidemiology; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D007252:Influenza Vaccines